🤖 Generated with AI assistance · Does not replace individualized medical advice.
AI-Driven Drug Repurposing: A Critical Review of Methods and Translational Readiness
AI Transparency Notice: This post was generated by an AI assistant to summarize and structure scientific literature for educational purposes. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult with a qualified oncologist for clinical decisions.
Lead
This 2026 narrative review synthesizes AI methodologies for drug repurposing, spanning classical machine learning to generative AI. While in silico performance is strong, the authors highlight a critical gap: external validation and clinical implementation remain scarce, necessitating rigorous prospective frameworks to translate computational promise into patient benefit.
Key Facts
| Domain | Key Insight |
|---|---|
| Scope | Covers 2018–2025 literature across six domains: ML, DL, GNNs, Generative AI, disease-specific apps, and databases. |
| Performance | Graph-based and transformer models currently represent the state-of-the-art on benchmark datasets. |
| Gap | Strong internal predictive performance often lacks external cohort validation and reproducible clinical outcomes. |
| Platforms | Highlights RepurposeDrugs, NeuroCADR, and COVID-19 frameworks based on transparency and validation. |
Why It Matters / Context
The conventional drug discovery pipeline is notoriously resource-intensive, often requiring more than a decade and billions of dollars to bring a single agent to market PMID: 42805095. Drug repurposing offers a pragmatic alternative by leveraging established safety profiles and known pharmacokinetics of approved or investigational drugs PMID: 42805095. However, the field has been fragmented, with limited comprehensive syntheses that critically evaluate the full spectrum of AI methodologies—from classical machine learning (ML) through deep learning (DL), graph neural networks (GNNs), and generative AI—while assessing their translational readiness PMID: 42805095.
For oncologists, this review is significant because it moves beyond the hype of “AI in drug discovery” to provide a structured comparison of data requirements, interpretability, and scalability across different AI architectures PMID: 42805095. It explicitly addresses the distinction between computational promise and realized clinical benefit, a crucial nuance for clinicians evaluating emerging repurposing trials in oncology, neurology, and infectious disease PMID: 42805095.
Details: Comparative Analysis of AI Architectures
The review synthesizes evidence across six thematic domains. Below is a summary of the comparative dimensions for the primary AI approaches discussed, highlighting their strengths and limitations in the context of drug repurposing.
| AI Approach | Primary Application in Repurposing | Data Requirements | Interpretability | Translational Readiness |
|---|---|---|---|---|
| Classical ML | Target-based and phenotypic screening | Moderate; relies on structured datasets | High; feature importance can be assessed | Moderate; established but limited by feature engineering |
| Deep Learning (DL) | Convolutional and recurrent networks for pattern recognition | High; requires large, labeled datasets | Low; “black box” nature | Moderate; strong in silico, variable in vivo |
| Graph Neural Networks (GNNs) | Biological network modeling (drug-target interactions) | High; requires complex graph-structured data | Low-Moderate; node/edge attention mechanisms | High (State-of-the-art); best benchmark performance |
| Generative AI / RL | De novo molecular design and optimization | Very High; requires extensive training data | Low; complex latent spaces | Low-Moderate; emerging, high potential for novel candidates |
Note: The review emphasizes that while GNNs and transformer models currently lead in benchmark performance, all approaches face challenges regarding dataset bias and regulatory uncertainty PMID: 42805095.
Limitations
⚠️ Critical Limitation Callout:The review explicitly states that external validation, reproducibility, and successful clinical implementation remain comparatively scarce PMID: 42805095.
* Dataset Bias: Models are often trained on biased datasets, limiting generalizability to diverse patient populations PMID: 42805095.
* Interpretability: The “black box” nature of DL and GNNs hinders clinical trust and regulatory approval PMID: 42805095.
* Infrastructure Gaps: Low-resource settings lack the computational infrastructure to deploy or validate these models PMID: 42805095.
* Regulatory Uncertainty: There is no standardized regulatory framework for AI-driven repurposing claims PMID: 42805095.
Clinicians should view AI-predicted repurposing candidates as hypotheses requiring rigorous prospective clinical validation, not as established therapeutic options.
Clinical Takeaway
When evaluating AI-driven drug repurposing candidates in oncology, prioritize studies that report external cohort validation and prospective experimental follow-up, as in silico performance alone is insufficient to predict clinical benefit PMID: 42805095.
Full Reference
Malik ZK, Ahmad K, Ahmed S. AI-driven drug repurposing: Methods, platforms, and translational applications. Computational Biology and Chemistry. 2026. PMID: 42805095 [DOI: 10.1016/j.compbiolchem.2026.109444]